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Background: Lupus anticoagulant (LA) is known to inhibit thrombin generation although patients have an
increased risk to develop thrombosis. We tried to determine whether thrombin generation is altered in plasma
samples of patients with abnormal test results in LA routine diagnostics and whether its measurement may
improve the risk assessment of thrombosis.
Methods: Samples from 63 patients (39 with abnormal test results; 24 controls) were included in the study.
Measurement of diluted Russel’s viper venom time (dRVVT) was part of the initial guideline conform diagnostic
procedure for detection of LA. In addition, measurement of anticardiolipin-IgM, -IgG and β2-glycoprotein-I-IgM, -IgG
were performed. Thrombin generation was measured using two different phospholipid concentrations in the
starting reagent.
Results: Analyzing all samples by logistic regression, thrombin generation after induction with high phospholipid
concentrations was the best predictor of thrombosis. After preselection of samples with alterations in dRVVT,
specificity of selected thrombin generation derived parameters for the detection of previous thrombosis increased
in this subgroup.
Conclusions: In patients with phospholipid-dependent prolongation of dRVVT, thrombin generation is variably
inhibited and the degree of inhibition corresponds to the occurrence of previous thrombosis. Measuring thrombin
generation in patients with phospholipid-dependent dRVVT prolongation may improve risk assessment of
thrombosis.
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Antiphospholipid syndrome (APS) is characterized by the
presence of antibodies against a complex of phospholipid-
binding protein and phospholipids. These antibodies are
primarily directed against the phospholipid-binding pro-
tein β2-glycoprotein I (β2-GPI) or cardiolipin (aCL) and
can be detected by ELISA. If the antibodies interfere with
coagulation assays they are described as lupus anticoagu-
lant (LA). Presence of the β2-GPI dependent LA was asso-
ciated with a high risk of thrombosis in a recent study [1].
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reproduction in any medium, provided the orin at least one of two specific tests with different assay
principles [2]. Depending on the number and type of as-
says positive for LA or the titer of LA the risk of develop-
ing thrombosis varies [3-5]. Very often, LA testing as part
of the APS testing is driven by a thrombotic event and pa-
tients receive anticoagulation depending on the positivity
in different assays and the titer detected [6,7]. However,
despite the high risk, recurrence does not occur in all pa-
tients [8,9]. Therefore, a better risk stratification seems to
be necessary.
Measurement of endogenous thrombin potential (ETP)
by thrombography has been attracting attention throughout
the last years. Although the methods lack standardization
[10] measurement of ETP has been analyzed in a wide var-
iety of patients. With respect to development of thrombosistd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with resistance against activated protein C [11], for the pre-
diction of recurrent venous thromboembolism [12,13], as a
screening tool for thrombophilic factors [14] and for the
detection of APS [15,16]. In the latter studies the effects on
thrombin generation in APS patients were particularly at-
tributed to the action of β2-GPI antibodies.
The hypothesis of the present study was that ETP and
parameters derived from the measurement of ETP (TG-
derived parameters) are altered in patients with abnormal
test results of LA diagnostics. It was further evaluated




Samples from 63 patients were retrospectively selected
from the LA testing program of the laboratory from
January to December 2009 (Figure 1). Indications for la-
boratory investigation were previous thrombosis, evalu-
ation of prolonged, activated partial thromboplastin time
and clinical history of systemic lupus erythematosus. In
case of previous thrombosis samples were collected im-
mediately after the event. Two tests were performed
routinely as recommended by established guidelines
[17]: (i) diluted Russel’s viper venome time (dRVVT;
LAC Screen/LAC Confirm) and (ii) MIXCON-LA. Sam-
ples with prothrombin time above reference range were
not included because prolonged clotting times may be
caused by anticoagulatory drugs. Twenty four nega-
tive plasma samples (negative in both screening tests)
were randomly selected as controls. All samples with ab-
normal findings in dRVVT confirmatory testing duringH istory of
ven ou s
th rom bosis






LAC Screen ratio neg.
Figure 1 Selection procedure of patients who were included in the stthe test period were included in the study if the suffi-
cient sample volume and a patient history were available
(39 samples). If a patient was repeatedly sampled during
the study period only the first sample was included in
the study.
Factor-V-Leiden mutation leads to altered thrombin
generation only after addition of activated protein C
(APC) [14,18] but not in native samples [13]. Therefore,
samples from heterozygous Factor-V-Leiden patients
were not excluded.
Laboratory investigation
Samples were centrifuged twice to obtain platelet-free
plasma [19] and stored at −80°C. All samples underwent
one freeze/thaw cycle (two aliquots, one for the initial
diagnostic and one back-up aliquot, were stored). LAC
Screen/Confirm (Instrumentation Laboratory, Kirchheim,
Germany) were measured according to the instructions of
the manufacturer on ACL Top analyzer (Instrumentation
Laboratory). Samples were LA-negative if the LAC Screen
test result was <45 s. Samples with LAC Screen > 45 s
were tested by LAC Screen ratio (LAC Screensample/ LAC
Screen normal plasma) and were negative if the ratio was
< 1.2. Samples with LAC Screen ratio > 1.2 were tested
with increased phospholipid concentrations by LAC
Confirm. Samples were included if the normalized ratio
(LAC Screenpatient/LAC Screennormal divided by LAC
Confirmpatient/LAC Confirmnormal) was ≥1.2.
Calibrated automated thrombin generation was mea-
sured in platelet-poor plasma using Bio-Tek FLx800 TC
fluorometer. Reagents, calibrators and controls were used
according to the recommendations of the manufacturer
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one with a low phospholipid concentration (RC low,
Tecnoclone) in the starting reagent as described re-
cently [20]. Coagulation was initiated with recombinant
human tissue factor. Conversion of substrate was
monitored for 60 minutes in 1 minute intervals. Lag
time, peak height of thrombin formation, time to peak
and area under the curve (ETP) were measured using Bio-
Tek KC 4/GEN 5 Software. All samples were analyzed
in dublicates. Antithrombin, protein C and protein S
were measured using routine methods (HemosIL Liquid
Antithrombin; HemosIL Protein C; HemosIL ProS;
Instrumentation Laboratory). Factor-V-Leiden and pro-
thrombin G20210A mutation were analyzed by PCR and
DNA hybridization (Hain Lifescience; Nehren, Germany).
aCL- and β2-GPI IgM/IgG were measured using the
Algeria® analyzer (Organtec, Mainz, Germany).
Statistical analysis
Imprecision was measured by repeated analysis (N = 16)
of one quality control sample. Calculations were per-
formed using Analyse-It (Analyse-it Software, Ltd.; Leeds,
UK), Excel (Microsoft, Unterschleissheim, Germany) and
SPSS 19 (IBM, New York, United States). Comparisons
between groups were performed by Mann–Whitney-
Wilcoxon-test. Information on the history of the pa-
tients was obtained from the hospital information system.
The study was approved by the local ethics committee.
Results
Patients
Characteristics of patients included in the study are sum-
marized in Table 1. Within the cohort only venous but no
arterial thrombotic events occurred. All patients with pre-
vious thrombotic events were considered as positive for
further analysis regardless whether one or more throm-
botic events were recorded in the patient’s history.Table 1 Characteristics of patients included in study
Female: male (absolute numbers) 38:25
number of patients with history of thrombosis 22
Location of thrombosis
lower extremity and pelvic veins 12
cerebral veins 3
pulmonary embolism 7
Number of patients tested/number of
patients positive for:
protein S deficiency 36/0
protein C deficiency 36/0
antithrombin deficiency 45/0
factor-V-Leiden mutation 37/6 heterozygous
prothrombin mutation 37/0Precision of the assay
Total imprecision for RC-low reagent were 11.7%,
14.6%, 12.9%, 8.1% and for RC-high reagent 11.7%,
11.5%, 10.8%, 6.0% with respect to lag time, time to
peak, peak height of thrombin formation and AUC.
Influence of β2-GPI and aCL antibodies on thrombin
generation
Comparison of TG-derived parameters between the
group with (N = 11) and the group without β2-GPI
IgM- and/or IgG-antibodies (N = 52) and between the
group with (N = 19) and without aCL IgM- and/or IgG-
antibodies (N = 44) revealed no significant differences.
(p > 0.05). Therefore, positivity for β2-GPI and aCL anti-
bodies was not considered for further analysis.
Forward stepwise logistic regression analysis for
prediction of thrombosis
All parameters (LAC Screen ratio, RC low and RC high:
lag time, thrombin peak concentration, time to peak and
AUC of thrombin generation) were included in a forward
stepwise logistic regression model to identify independent
predictors of thrombosis. Using this model variables were
selected in the order in which they maximize the statisti-
cally significant contribution to the model. Variables were
stepwise included in the order which they contribute to
the model and the model is recalculated until only vari-
ables with p < 0.05 remain. Of all parameters tested
RC-high AUC was the best independent predictor of
thrombosis (Table 2).
Comparison of TG-derived parameters and LAC Screen
test result between patients without and with thrombosis
TG-derived parameters differed significantly (except peak
thrombin generation with RC-low reagent) between sam-
ples from patients with and without thrombosis (Figure 2)
while there was no significant difference in LAC Screen
ratio. Further analysis of the dot plots revealed a wide
spreading of the results most noticeably for the TG-
derived parameters time to peak and AUC. Therefore,
samples were further subdivided into LAC Screen ratio
negative (< 1.2) and positive (> =1.2) samples with and
without history of thrombosis.Table 2 Logistic regression analysis of all TG-derived
parameters and LAC Screen ratio as independent






Wald test p Exp (B)
RC-high AUC −0.001 0.000 9.434 (df = 1) 0.002 0.999
Constant 1.653 0.831 3.953 (df = 1) 0.047 5.223
Analysis was performed by forward inclusion. Variables were stepwise
included if p – value was < 0.05 and the model is recalculated until only
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Figure 2 Box-Whisker- and dot plots of 4 TG-derived parameters (lag time, time to peak, peak thrombin, AUC of thrombin generation)
and LAC Screen ratio after induction with 2 different starting reagents (RC-low = low phospholipid concentration, RC-high = high
phospholipid concentration). Significance level was 0.05.
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Screen negative/positive patients without and with
thrombosis
Comparison between the subgroups revealed that TG-
derived parameters after induction with RC low reagent
differed significantly between samples from patients with
history of thrombosis/positive LAC Screen ratio and the
other samples (Figure 3). After induction with RC high
reagent significant differences were only noticed be-
tween the thrombosis negative patients (independent of
LAC Screen ratio) and patients with thrombosis/positive
LAC Screen ratio (Figure 3).
ROC-analysis of TG-derived parameters for the prediction
of previous thrombosis
Performing ROC (receiver operating characteristics)-ana-
lysis of all TG-derived parameters on preselected, LAC
Screen ratio positive samples (N = 29; 13 thrombosis, 16
non-thrombosis) revealed high AUC (area under thecurve) for all parameters with respect to previous throm-
bosis (Table 3). ROC-analysis was also performed for the
samples with a negative LAC Screen ratio (N = 34; 9
thrombosis, 25 non-thrombosis). However, in this group
most TG-derived parameters were not or less pronounced
discriminatory between the thrombosis-negative and
thrombosis-positive patients (Table 3).
Four samples had to be excluded from analysis be-
cause thrombin generation was inhibited and data could
not be further analyzed. This occurred in three samples
with positive LAC Screen/LAC Confirm ratio but in one
case also in the LAC Screen/LAC Confirm ratio negative
group. In this sample from a patient with thrombosis the
other initially performed screening test MIXCON-LA
ratio was altered.
Discussion
Patients with LA have an increased risk to develop
thrombosis. In clinical practice, testing usually follows a
Figure 3 Box-Whisker- and dot plots of 4 TG-derived parameters (lag time, time to peak, peak thrombin, AUC of thrombin generation)
after induction with 2 different starting reagents (RC-low = low phospholipid concentration, RC-high = high phospholipid concentration).
Patients are sorted according to the result of the LAC Screen ratio and clinical history of thrombosis. Results were compared by Mann–Whitney-
Wilcoxon test. If not indicated otherwise comparison was statistically non-significant. Significance level was 0.05.
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accordance with current guidelines, LA has to be
screened for by a combination of two assays on two
different occasions. Depending on the assays used dif-
ferent predictive values have been described for the
detection of patients with previous thrombosis [1,21].
However, stratification according to risk of thrombosis
or recurrence is a prerequisite to selectively provide
those patients with antithrombotic medication who
benefit. The measurement of TG-derived parametersTable 3 ROC-analysis of TG-derived parameters for the detect
preselected by LAC Screen ratio (LAC screen ratio >= 1.2 and
TG-derived parameter ROC (95% CI)
(LAC-S ratio >=1.2) N = 29
Case
dRVVT 0.46 (0.24 - 0.68)
RC-low lag time 0.76 (0.56 - 0.97) 2 thrombosi
RC-low peak height of
thrombin formation
0.80 (0.57 - 1.00) 2 thrombosi
RC-low time to peak 0.80 (0.58 - 1.00) 2 thrombosi
RC-low AUC 0.81 (0.57 - 1.00) 2 thrombosi
RC-high lag time 0.83 (0.68 - 0.98) 2 t
RC_high peak height of
thrombin formation
0.82 (0.60 - 1.00) 2 t
RC_high time to peak 0.80 (0.61 - 0.99) 2 t
RC-high AUC 0.83 (0.60 - 1.00) 2 tin addition to other assays might increase diagnostic
specificity.
In general, prolongation of time to peak and lag time
on one hand and decrease of peak height of thrombin
formation and AUC on the other hand were observed
predominantly in samples in which a phospholipid-
dependency of the coagulation inhibitor had already
been proven before. This has already been shown for
LA in the past [15,16]. Association between of β2-GPI
and aCL antibodies and prolongation of lag time/reducedion of previous thrombosis in samples from patients
LAC screen ratio < 1.2)
s excluded ROC (95% CI)
(LAC-S ratio <1.2) N = 34
Cases excluded
none Not calculated Not determined
s 1 non-thrombosis 0.59 (0.36 - 0.82) 1 thrombosis
s 1 non-thrombosis 0.51 (0.30 - 0.72) 1 thrombosis
s 1 non-thrombosis 0.50 (0.27 - 0.73) 1 thrombosis
s 1 non-thrombosis 0.57 (0.35 - 0.78) 1 thrombosis
hrombosis 0.72 (0.53 - 0.91) 1 thrombosis
hrombosis 0.61 (0.39 - 0.83) 1 thrombosis
hrombosis 0.70 (0.50 - 0.90) 1 thrombosis
hrombosis 0.67 (0.46.- 0.87) 1 thrombosis
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present study the number of antibody-positive patients
was small and no significant alteration in any of the TG-
derived parameters was observed. Recently Ninnivaggi
et al. [23] described that preincubation with phospholipids
was necessary to induce a conformational change of β2-
GPI resulting in alterations of thrombin generation.
Therefore, different testing procedures and the lack of
positivity for β2-GPI antibodies in LA-positive patients
which has been attributed to the insufficient sensitivity of
currently available test kits [15] might have caused the dif-
fering results. Because analysis of the effects of β2-GPI
antibody positivity was not the main focus of this study
this aspect could not be studied further.
When comparing TG-derived parameters between
patient with and without thrombosis a relatively wide
spreading of the results was detected. Therefore, samples
where subdivided further on the basis of the LAC Screen
ratio result. This resulted in a more homogeneous distri-
bution of the results. Most notably samples from pa-
tients with a positive LAC Screen ratio and a history of
thrombosis differed significantly from samples of other
patients.
To further analyze this relationship ROC-analysis on
these preselected samples was performed to test whether
use of TG-derived parameters increased specificity for
the identification of patients with previous thrombosis.
This resulted in high AUC for all parameters analyzed. It
is noteworthy that samples from four patients had to be
excluded from analysis because thrombin generation was
inhibited and did not provide a reliable result. Among
those were two patients with a history of thrombosis.
Thus, one could speculate that inhibition of thrombin
generation is highly associated with a history of
thrombosis.
Acquired resistance against APC has been suggested
as a mechanism of LA to induce thrombosis [24-26]. In
hereditary APC resistance (factor V Leiden mutation)
thrombin generation is not altered [13] and APC has to
be added to observe effects on thrombin generation as-
says [14,18]. However, in acquired APC resistance pro-
longation of lag time and reduced thrombin generation
[27] were described without adding APC. Based on these
data one could hypothesize that acquired LA-induced
APC resistance is one important underlying mechanism
of LA-associated thrombosis as it has already been hy-
pothesized in a recent publication [28]. If patients had a
higher thrombotic risk, testing by thrombography or
perhaps also for acquired APC resistance supplementing
the established work-up could result in different stratifi-
cation with respect to medication and improve the out-
come of patients.
The most serious limitation is the retrospective char-
acter of the study. In other studies a thrombogenic statehas been associated with increased thrombin generation
[12,13]. In our study decreased thrombin generation was
noticed and this was predominantly observed in samples
with positive dRVVT. In most of these samples a yet un-
confirmed LA might have been present because LA has
also been shown to inhibit thrombin generation [15,16].
However, the risk of previous thrombosis does not ne-
cessarily reflect the risk of future thrombosis. This as-
pect can only be addressed by a prospective study in a
larger patient cohort. The latter approach could also
avoid a second shortcoming of the study because not all
but only randomly selected LA-negative samples from
the study period were included as controls. Therefore,
positive samples were overrepresented which might have
biased the analysis.
Another limitation of the study was that only samples
with abnormal initial test results and not diagnostically
proven LA-positive samples were included. In some pa-
tients coagulation assays may have normalized within
the following 12 weeks. However, this does not necessar-
ily affect the interpretation of the results because the
analysis was not based on the diagnosis LA (“yes” or
“no”) but on the initial, quantitative changes in coagula-
tion assays which are most likely associated with the
titer of a coagulation inhibitor the latter being in most
cases LA.
Conclusions
TG-generation is reduced in samples from patients with
alterations detected by dRVVT hinting towards the pres-
ence of LA. In addition, presence of reduced thrombin
generation in these samples was associated with a his-
tory of thrombosis. Therefore, TG should be evaluated
in a larger patient collective with respect to it diagnostic
role when testing for LA.
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